The Senate bill to allow the government to negotiate prices of Medicare drugs likely would result in fewer new drugs being available, The Wall Street Journal said in an editorial. The newspaper likened the bill to price controls and said the result would be less incentive for drugmakers to invest in the development of new medicines.

Related Summaries